Table 2.
Number and Proportion of Patients with Claims for Clinical Manifestations of aHUS from 0 to 3 Months Preindex to 6 Months Postindex by Cohort
| Clinical Manifestation | Switch |
Ravulizumab Only |
Eculizumab Only |
|---|---|---|---|
| (n=65) | (n=9) | (n=248) | |
| Anemia, n (%) | |||
| 0-3 mo preindex | 12 (18) | 3 (33) | 122 (49) |
| 0-3 mo postindex | 9 (14) | 3 (33) | 100 (40) |
| 3-6 mo postindex | 9 (14) | 1 (11) | 76 (31) |
| Hemolytic anemia, n (%) | |||
| 0-3 mo preindex | 3 (5) | 0 (0) | 37 (15) |
| 0-3 mo postindex | 4 (6) | 2 (22) | 27 (11) |
| 3-6 mo postindex | 3 (5) | 1 (11) | 16 (6) |
| Hypertension, n (%) | |||
| 0-3 mo preindex | 27 (42) | 7 (78) | 131 (53) |
| 0-3 mo postindex | 18 (28) | 5 (56) | 124 (50) |
| 3-6 mo postindex | 21 (32) | 5 (56) | 101 (41) |
| Proteinuria, n (%) | |||
| 0-3 mo preindex | 4 (6) | 2 (22) | 24 (10) |
| 0-3 mo postindex | 3 (5) | 2 (22) | 18 (7) |
| 3-6 mo postindex | 2 (3) | 0 (0) | 13 (5) |
| Thrombocytopenia, n (%) | |||
| 0-3 mo preindex | 6 (9) | 3 (33) | 62 (25) |
| 0-3 mo postindex | 2 (3) | 3 (33) | 38 (15) |
| 3-6 mo postindex | 6 (9) | 1 (11) | 33 (13) |
| CKD, n (%) | |||
| 0-3 mo preindex | 25 (38) | 6 (67) | 102 (41) |
| 0-3 mo postindex | 20 (31) | 5 (56) | 110 (44) |
| 3-6 mo postindex | 18 (28) | 4 (44) | 104 (42) |
| Kidney failurea, n (%) | |||
| 0-3 mo preindex | 23 (35) | 7 (78) | 118 (48) |
| 0-3 mo postindex | 17 (26) | 8 (89) | 103 (42) |
| 3-6 mo postindex | 16 (25) | 7 (78) | 74 (30) |
Note: For the treatment-switch patients, those receiving ravulizumab only, and those receiving eculizumab only, a total of 65, 9, and 248 patients in these cohorts, respectively, had data available from 3 months preindex to 6 months postindex.
Abbreviations: aHUS, atypical hemolytic uremic syndrome; CKD, chronic kidney disease.
a
Kidney failure was formerly known as end-stage renal disease.